ScinoPharm Taiwan Ltd 2024 IR
The report outlines ScinoPharm Taiwan, Ltd.'s financial and operational performance for the fiscal year 2024, highlighting a consolidated revenue of NT$3.406 billion and a net profit after tax of NT$339 million. The company made significant progress in its proprietary active pharmaceutical ingredients (APIs), proprietary formulations, and contract development and manufacturing (CDMO) services, passing FDA and ANVISA inspections with zero deficiencies. ScinoPharm also advanced its corporate sustainability efforts, completing third-party verification of the carbon footprint of its core API products in accordance with ISO 14067 and receiving multiple sustainability awards. Additionally, the company implemented energy-saving measures, reducing its Scope 1 and Scope 2 greenhouse gas emissions by approximately 5.69% compared to 2023.
Company: ScinoPharm Taiwan Ltd
Sector: Health Care
Country: Taiwan
Year: 2024
Type: IR
Pages: 178
ScinoPharm Taiwan Ltd
Annual Report
The report outlines ScinoPharm Taiwan, Ltd.'s financial and operational performance for the fiscal year 2024, highlighting a consolidated revenue of NT$3.406 billion and a net profit after tax of NT$339 million. The company made significant progress in its proprietary active pharmaceutical ingredients (APIs), proprietary formulations, and contract development and manufacturing (CDMO) services, passing FDA and ANVISA inspections with zero deficiencies. ScinoPharm also advanced its corporate sustainability efforts, completing third-party verification of the carbon footprint of its core API products in accordance with ISO 14067 and receiving multiple sustainability awards. Additionally, the company implemented energy-saving measures, reducing its Scope 1 and Scope 2 greenhouse gas emissions by approximately 5.69% compared to 2023.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Mar 31, 2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Employees